For the quarter ending 2025-09-30, GUTS had $55,366K increase in cash & cash equivalents over the period. -$22,722K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -45,603 | -51,624 |
| Depreciation | 290 | 560 |
| Non-cash interest expense | 72 | 155 |
| Non-cash operating lease expense | 400 | 774 |
| Stock-based compensation expense | 1,638 | 3,191 |
| Change in fair value of warrant liabilities | 21,201 | -477 |
| Change in fair value of notes payable, non-cash | 785 | -177 |
| Inventory | 0 | -73 |
| Prepaid expenses and other current assets | -2,351 | 171 |
| Accounts payable | -2,655 | 671 |
| Accrued expenses and other current liabilities | -811 | 1,394 |
| Operating lease liabilities | -318 | -605 |
| Other long-term assets and liabilities | 64 | 42 |
| Net cash used in operating activities | -22,714 | -46,278 |
| Purchases of property and equipment | 8 | 546 |
| Net cash used in investing activities | -8 | -546 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | 0 | 0 |
| Issuance of common stock in connection with at-the-market offering, net of issuance costs | 477 | 1,592 |
| Issuance of common stock and warrants in the august 2025 public offering, net of underwriting commissions and offering costs | 21,328 | - |
| Issuance of common stock in the september 2025 offering, net of underwriting commissions and offering costs | 56,400 | - |
| Proceeds from exercise of stock options | 0 | 280 |
| Principal payments on finance lease obligations | 117 | 221 |
| Net cash provided by financing activities | 78,088 | 1,651 |
| Net increase in cash, cash equivalents and restricted cash | 55,366 | -45,173 |
| Cash and cash equivalents at beginning of period | 71,719 | - |
| Cash and cash equivalents at end of period | 81,912 | - |
FRACTYL HEALTH, INC. (GUTS)
FRACTYL HEALTH, INC. (GUTS)